EUVIMEDEUVIMED entdecken
Crossref

Investigation of the Effect of Lasmiditan on the Pharmacokinetics of P‐Glycoprotein and Breast Cancer Resistance Protein Substrates

Debra Luffer-Atlas, Darren Wilbraham, Maria M Posada, John Landry, Max Tsai, Eric M Pearlman

The Journal of Clinical Pharmacology · 2024

DOI: 10.1002/jcph.2328 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2024. Verfasst von Debra Luffer-Atlas und 5 weiteren Autor:innen. Beteiligte Einrichtung: Eli Lilly and Company, Indianapolis, IN, USA. Hauptthemen laut MEDLINE: ATP Binding Cassette Transporter, Subfamily B, Member 1, Breast Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lasmiditan is an in vitro inhibitor of P‐glycoprotein (P‐gp) and breast cancer resistance protein (BCRP) efflux transporters. We aimed to confirm predictions from physiologically based pharmacokinetic models of lasmiditan, and assess the safety and tolerability of rosuvastatin and dabigatran co‐administered with lasmiditan. In this open‐label, post‐marketing drug–drug interaction, phase 1 clinical trial, eligible participants were adults aged 21‐70 years with a body mass index of 18.5‐35.0 kg/m 2 . Part 1 (P‐gp, 150 mg dabigatran etexilate with 200 mg lasmiditan) and part 2 (BCRP, 10 mg rosuvastatin with 200 mg lasmiditan) employed similar designs: a single dose of probe substrate administered on day −2 with pharmacokinetic evaluation; 1‐week washout; lasmiditan administered on days 8 and 9 alone; lasmiditan co‐administered with a single dose of probe substrate on day 10, with pharmacokinetic evaluation of probe substrate and lasmiditan. Sixty‐six participants were included in part 1 and 30 participants were included in part 2. Following dabigatran co‐administration with lasmiditan, versus dabigatran alone, 90% confidence intervals for geometric least‐squares (LS) mean ratios of area under the plasma concentration–time curve from time 0 extrapolated to infinity (AUC 0–∞ ) and maximum observed drug concentration (C max ) were not contained within the non‐effect boundaries (0.80 to 1.25). Dabigatran AUC 0–∞ increased by 25% and C max increased by 22%. The median time of maximum observed drug concentration (t max ) for dabigatran was 2.0 to 3.0 hours. Following rosuvastatin co‐administration with lasmiditan, versus rosuvastatin alone, 90%CIs for geometric LS mean ratios of AUC 0–∞ and C max were contained within non‐effect boundaries (0.80‐1.25). Rosuvastatin AUC 0–∞ increased by 15% and C max increased by 7%. The median t max for rosuvastatin was 4.0 hours. Results suggest that lasmiditan has a weak effect on P‐gp substrates and no clinically relevant effect on BCRP substrates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ATP Binding Cassette Transporter, Subfamily B, Member 1Breast NeoplasmsAdultFemaleHumansArea Under CurveATP Binding Cassette Transporter, Subfamily G, Member 2Cross-Over StudiesDabigatranDrug InteractionsNeoplasm ProteinsRosuvastatin CalciumYoung AdultMiddle AgedAgedBenzamidesPiperidinesPyridines

Stichwörter der Autor:innen

drug-drug interactionslasmiditanmigrainepharmacokinetics

Substanzen

ATP Binding Cassette Transporter, Subfamily B, Member 1ATP Binding Cassette Transporter, Subfamily G, Member 2DabigatranNeoplasm ProteinsRosuvastatin CalciumlasmiditanBenzamidesPiperidinesPyridines

Autor:innen und Institutionen

  • Eli Lilly and Company, Indianapolis, IN, USA.
  • Eli Lilly and Company, Bracknell, UK.
  • Eli Lilly Canada, Inc., Toronto, ON, Canada.

Zitieren

APA

Luffer-Atlas, D., Wilbraham, D., Posada, M. M., Landry, J., Tsai, M., & Pearlman, E. M. (2024). Investigation of the Effect of Lasmiditan on the Pharmacokinetics of P‐Glycoprotein and Breast Cancer Resistance Protein Substrates. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.2328

Vancouver

Luffer-Atlas D, Wilbraham D, Posada MM, Landry J, Tsai M, Pearlman EM. Investigation of the Effect of Lasmiditan on the Pharmacokinetics of P‐Glycoprotein and Breast Cancer Resistance Protein Substrates. The Journal of Clinical Pharmacology. 2024. doi:10.1002/jcph.2328

BibTeX
@article{LufferAtlas2024,
  author = {Luffer-Atlas, Debra and Wilbraham, Darren and Posada, Maria M and Landry, John and Tsai, Max and Pearlman, Eric M},
  title = {Investigation of the Effect of Lasmiditan on the Pharmacokinetics of P‐Glycoprotein and Breast Cancer Resistance Protein Substrates},
  journal = {The Journal of Clinical Pharmacology},
  year = {2024},
  doi = {10.1002/jcph.2328}
}
Kostenlos starten →